Clicky

Guardant Health, Inc.(GH)

Description: Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.


Keywords: Medicine Cancer Biopharmaceutical Disease Oncology Telemedicine Telehealth Clinical Development Blood Test Precision Medicine Lab Testing Biopsy Healthcare Costs

Home Page: guardanthealth.com

GH Technical Analysis

505 Penobscot Drive
Redwood City, CA 94063
United States
Phone: 855 698 8887


Officers

Name Title
Dr. Helmy Eltoukhy Ph.D. Co-Founder, Co-CEO & Chairman
Dr. AmirAli Talasaz Ph.D. Co-CEO & Director
Mr. Michael Bell Chief Financial Officer
Mr. John G. Saia Chief Legal Officer
Dr. Craig Eagle M.D. Chief Medical Officer
Mr. Christopher Freeman Chief Commercial Officer of Oncology Bus.
Mr. Andy Ament Sr. VP of Operations
Darya Chudova Sr. VP of Technology
Mr. Kumud Kalia Chief Information Officer
Ms. Jennifer Higgins VP of Public Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 25.9492
Price-to-Sales TTM: 9.8119
IPO Date: 2018-10-04
Fiscal Year End: December
Full Time Employees: 1373
Back to stocks